Overview

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, Phase III, open-label, multicenter study.
Phase:
Phase 3
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
Bristol-Myers Squibb
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Epothilones
Liposomal doxorubicin
Paclitaxel